FORCE’s eXamining the Relevance of Articles for Young Survivors (XRAYS) program is a reliable resource for breast cancer research-related news and information. XRAYS reviews new breast cancer research, provides plain-language summaries, and rates how the media covered the topic. XRAYS is funded by the CDC.
The phase III MONALEESA-7 study is a clinical trial looking at the effect of a type of treatment known as a CDK4/6 inhibitor in pre- or perimenopausal women with hormone receptor–positive advanced breast cancer. (7/22/19)
The POLO clinical trial looks at whether the PARP inhibitor olaparib improves outcomes for those with metastatic pancreatic cancer after platinum-based chemotherapy. (7/3/19)
The KATHERINE trial looked at the benefit of the new drug, Kadcyla, for treating early-stage breast cancer after surgery and chemotherapy. The results of this study led to FDA approval in May 2019. (6/17/19)
Research reported at the 2019 annual meeting of the American Society of Clinical Oncology establishes a link between dietary fat intake and its impact on postmenopausal women’s risk of dying from breast cancer. (6/13/19)
The FDA approved the use of the immunotherapy drug Tecentriq (atezolizumab) in combination with the chemotherapy agent Abraxane (nab-paclitaxel) for certain patients with advanced triple-negative breast cancer.
We report results of an early-stage clinical trial of a new class of drugs for metastatic triple-negative breast cancer (TNBC). IMMU-132 is an antibody-drug conjugate, meaning that it combines two different molecules: an antibody that targets certain proteins or tumor markers and delivers SN-38, a chemotherapy drug that can kill tumor cells. This study looks at whether IMMU-132 is safe and effective for treating metastatic TNBC. (4/16/19)
The Jerusalem Post published an article titled, “A cure for cancer? Israeli scientists may have found one.” The story profiled a small Israeli company called Accelerated Evolution Biotechnologies that has been working on developing new cancer treatments since 2000. The article relied almost entirely on an interview with the company’s chairperson of the board who made a series of unsubstantiated claims that included that, in a year’s time, the company will offer a complete cure for cancer. (2/12/19)
Several recent studies on the cost of cancer care show the negative effects on cancer patients. In this XRAYS we review a recent article by Kaiser Health News and associated studies about the financial impact of breast cancer treatment and cost of precision medicine. (2/8/19)
The PALOMA-3 clinical trial showed that a new CDK4/6 inhibitor in combination therapy improved progression-free survival of women treated for hormone receptor-positive, HER2-negative advanced or metastatic breast cancer in women with prior disease progression after endocrine therapy. This XRAYS reviews a newly published study in the New England Journal of Medicine that looks at overall survival in the original PALOMA-3 study. (1/23/19)
Fertility issues and family planning decisions are prominent concerns for young women with breast cancer. This XRAYS looks at Dr. Ann Partridge’s presentation at the 2018 San Antonio Breast Cancer symposium. Her talk, “Breast cancer in young women: Understanding differences to improve outcomes," focused on initial findings from the Young Women's Breast Cancer Study. Dr. Partridge’s research continues in the currently enrolling POSITIVE trial which tests whether women can safely interrupt adjuvant endocrine therapy in order to get pregnant. (1/7/19)
In the Saturday essay of The Washington Post, Dr. Pamela Munster recounts her family's history with cancer associated with a mutation in the BRCA2 gene. She details her father's extraordinary journey with pancreatic cancer, one of the most aggressive and deadly cancers. (11/27/18)
This article by journalists Caroline Chen and Riley Wong looks at racial disparities between participation in clinical trials and the population of people with cancer. (11/6/18)
Metastatic breast cancer is often difficult to treat. In a new approach, called adoptive cell therapy (ACT), a patient’s own T-cells (a type of cancer-fighting immune cells) are collected, multiplied in a lab, and then returned to the patient. The goal is to enhance the patient’s immune system with many more T-cells that recognize and attack metastasized tumor cells. This study reports on a single patient whose
metastatic breast cancer is still in remission (no evidence of disease) after more than 22 months following ACT. (8/16/18)
Current breast cancer treatments can negatively affect cardiovascular health. Recently, the American Heart Association released its first scientific statement on cardiovascular disease and breast cancer. This statement includes a comprehensive overview of the prevalence of both diseases, shared risk factors, cardiotoxic effects of therapy and the prevention and treatment of cardiovascular disease in breast cancer patients. (5/2/18)
Immunotherapy is treatment that uses the immune system to fight cancer. Still in its infancy, it is a promising therapy that is changing how certain cancers are treated. A new study reports that tumors in lab mice were eliminated when they were injected with two immune system-enhancing agents. This new approach is called in situ (at the original site) vaccination because the injections are given directly into the tumors. It worked on several different types of mouse tumors, including lymphomas and breast tumors. This approach may be safer than conventional
immunotherapy because it uses very low doses of the agents and it does not require tumors to have particular markers. (02/23/18)
Some breast cancer patients are given
neoadjuvant (before surgery) chemotherapy. However, some recent studies have raised concerns that neoadjuvant treatment might actually trigger cancer spread in certain situations. In the current study, researchers used mouse models and human breast cancers to explore this possibility. (10/10/17)
Barbara Jacoby's Huffington Post piece, "How do breast cancer and metastatic breast cancer differ?" emphasizes the need for more treatment options for patients with advanced breast cancer.